	Possible Contribution of Multiple Sclerosis Pathology to Treatment-Resistant Schizophrenia: A Case Study. Neuropsychopharmacol Rep Miura S, Nagaoka A, Hino M, Shishido R, Hatano M, Hosogai Y, Miyahara K, Oba Y, Kaneko K, Kunii Y, Tomita H. PMID: 42559701 [PubMed - indexed for MEDLINE]
	Delusional themes and forensic status in schizophrenia spectrum disorders: a machine learning based discriminative study. Front Psychol Eleryan AAN, Boudriot F, Dörner M, Hofmann AB, Machetanz L, Kirchebner J. PMID: 42558267 [PubMed]
	Cancer-related mortality among individuals withÂ schizophrenia: systematic review and meta-analysis of cohort studies. BJPsych Open Mahdavinoor SMM, Mollaei A, Golzar A, Kargar-Soleimanabad S, Bordbari AH, Amiri M, Rafiee MH, Seddigh L. PMID: 42557898 [PubMed]
	Dopamine Receptor D2 gene Polymorphisms rs2005313, rs4274224, and rs4938019 in Pakistani Patients with Schizophrenia:a Diagnostic Tool for Schizophrenia. J Mol Neurosci Yaseen I, Ahmad S, Ghalib M, Aslam MS, Tariq R, Sajjad O, Yaseen F. PMID: 42557473 [PubMed - indexed for MEDLINE]
	Feasibility Trial of a Health Behaviours Promotion Group for Youth at Clinical High Risk for Psychosis. Early Interv Psychiatry Ruiz-Yu B, Diaz T, Hernandez D, Zinberg J, Miklowitz DJ, Bearden CE. PMID: 42552232 [PubMed - indexed for MEDLINE]
	Psychotic Vulnerability in Adolescents With Obsessive-Compulsive Disorder: First Longitudinal Evidence From a Prospective Pilot Study. Early Interv Psychiatry Borrelli DF, Gambolò L, Di Donna A, Marchesi C, Tonna M. PMID: 42554468 [PubMed - indexed for MEDLINE]
	Clinical and Demographic Characteristics in Schizophrenia Patients with and without a History of Taking Long-acting Injectable Antipsychotics: A Comparative Cross-sectional Study. J Res Pharm Pract Boskabadi SJ, Zarghami M, Fariborzifar A, Moosazadeh M, Hendouei N. PMID: 42553850 [PubMed]
	Effect of SMS Reminders on Medication Adherence in Schizophrenia: A Quasi-Experimental Study in Nigeria. Niger Med J Yakubu AA, Bashar SM, Aveka AI, Murinyi MM, Khalid S, Yakasai BA. PMID: 42553841 [PubMed]
	Evaluation of a hybrid asynchronous-synchronous delivery model for family intervention in psychosis: the psychosis REACH program. Front Digit Health Kopelovich SL, Blank J, Vaswani-Bye A, Shepard V, Buckland HT, Hardy K, Turkington D. PMID: 42553243 [PubMed]
	Latest developments in the use of e-cigarettes by people with schizophrenia spectrum disorders who smoke: a scoping review. Front Psychiatry Caponnetto P, Pratt S, Bellanca CM, Vitale NM, Prezzavento GC, La Rosa GRM, Adebisi YA, Nilforooshan R, John I, Fakhrou A, Petralia A, Signorelli MS, Pikirenia U, Testoni I, Cavallaro R, Bosia M, Polosa R. PMID: 42553197 [PubMed]
	CB1 receptor-enriched functional connectivity analysis revealed target-specific modulation by cannabidiol in early psychosis. J Psychopharmacol Lombardi G, Shatalina E, O'Neill A, Wilson R, Mehta M, Bhattacharyya S. PMID: 42552898 [PubMed - as supplied by publisher]
	The Mediating Role of Metacognitive Beliefs in Self-Compassion and Schizophrenia Recovery. Brain Behav Darwish SS, Al-Sarahneh A, Dibas M, Ali A, Hamed A, Barakat A, Othman A, ElBoraie H, Hamzaa H, Ali W. PMID: 42552873 [PubMed - indexed for MEDLINE]
	Astroglial dysregulation and gliotransmitter imbalance in schizophrenia. Int Rev Neurobiol Babu Deva Irakkam MP, Kandasamy M. PMID: 42552049 [PubMed - indexed for MEDLINE]
	Muscarinic agonists for schizophrenia: Bridging preclinical evidence and clinical enthusiasm. Br J Pharmacol Morris BJ, Pratt JA. PMID: 42551974 [PubMed - as supplied by publisher]
	Evolving patterns of antipsychotic use and polypharmacy for schizophrenia in Hong Kong: a 21-year longitudinal study. Psychiatry Res Deng EK, Yan VK, Leung SM, Wei Y, Lee KJ, Huang C, Kan CK, Lai FTT, Wong IC, Chen EYH, Chan EW. PMID: 42551239 [PubMed - as supplied by publisher]
	Medium-term prediction of clinically relevant outcomes in first-episode schizophrenia patients. Schizophr Res Bakstein E, Kudelka J, Schneider J, Slovakova A, Fialova M, Ihln M, Furstova P, Hlinka J, Spaniel F. PMID: 42551145 [PubMed - as supplied by publisher]
	Correlates of Engagement and Associations With Outcomes in a Cannabis Harm-Reduction Mobile App for Youth With First-Episode Psychosis: Exploratory Analysis of the CHAMPS Pilot Randomized Controlled Trial. JMIR Form Res Mahroug A, Lachance-Touchette P, Coronado-Montoya S, Abdel-Baki A, Côté J, Crocker C, Crockford DN, Daneault JG, Dubreucq S, Dussault-Laurendeau M, Fischer B, Lecomte T, L'Heureux S, Ouellet-Plamondon C, Roy MA, Tatar O, Tibbo PG, Villeneuve M, Wittevrongel A, Jutras-Aswad D. PMID: 42550986 [PubMed - indexed for MEDLINE]
	Accelerated, Neuronavigated Neuromodulation for Negative Symptoms in Schizophrenia: Protocol for a Randomized Controlled Pilot Trial. Sante Ment Que Choucroun A, Roy O, Potvin S, Palaniyappan L, Zeramdini N, Aiyaar A, Picard K, Zanjani S, Parekh D, Markessinis M, Friesen T, Zamorano T, Diaconescu A, Lepage M, Powers A, Shah J, Zavaglia E, Benrimoh D. PMID: 42550441 [PubMed - indexed for MEDLINE]
	[Spirituality and cortisol in people living with schizophrenia: An exploratory study]. Sante Ment Que Poulin A, Lupien S, Consortium Signature. PMID: 42550433 [PubMed - indexed for MEDLINE]
	Efficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trial. Eur Arch Psychiatry Clin Neurosci Chakraborty R, Mohapatra D, Biswas T, Ramasubbu MK, Maiti R, Mishra A, Mishra BR. PMID: 42550195 [PubMed - as supplied by publisher]

Articles 1 - 20 / 69519

Page 1 of 3476



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy